Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction.
COVID-19
Dermatitis
Edema
Erythema
Inflammation
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
25 Aug 2021
25 Aug 2021
Historique:
received:
08
05
2021
accepted:
20
07
2021
entrez:
26
8
2021
pubmed:
27
8
2021
medline:
4
9
2021
Statut:
epublish
Résumé
The coronavirus disease 2019 (COVID-19) is associated with a wide clinical spectrum of skin manifestations, including urticarial, vesicular, vasculitic and chilblain-like lesions. Recently, delayed skin reactions have been reported in 1% individuals following mRNA vaccination against SARS-CoV-2. The exact pathophysiology and the risk factors still remain unclear. 6821 employees and patients were vaccinated at our institutions between February and June 2021. Every patient received two doses of the mRNA-1273 vaccine in our hospitals, and reported back in case of any side effects which were collected in our hospital managed database. Eleven of 6821 vaccinated patients (0.16%) developed delayed skin reactions after either the first or second dose of the mRNA-1273 vaccine against SARS-CoV-2. Eight of 11 patients (73%) developed a rash after the first dose, while in 3/11 (27%), the rash occurred after the second dose. More females (9/11) were affected. Four of 11 patients required antihistamines, with two needing additional topical steroids. All the cutaneous manifestations resolved within 14 days. None of the skin reactions after the first dose of the vaccine prevented the administration of the second dose. There were no long-term cutaneous sequelae in any of the affected individuals. Our data suggests that skin reactions after the use of mRNA-1273 vaccine against SARS-CoV-2 are possible, but rare. Further studies need to be done to understand the pathophysiology of these lesions.
Sections du résumé
BACKGROUND
BACKGROUND
The coronavirus disease 2019 (COVID-19) is associated with a wide clinical spectrum of skin manifestations, including urticarial, vesicular, vasculitic and chilblain-like lesions. Recently, delayed skin reactions have been reported in 1% individuals following mRNA vaccination against SARS-CoV-2. The exact pathophysiology and the risk factors still remain unclear.
PATIENTS AND METHODS
METHODS
6821 employees and patients were vaccinated at our institutions between February and June 2021. Every patient received two doses of the mRNA-1273 vaccine in our hospitals, and reported back in case of any side effects which were collected in our hospital managed database.
RESULTS
RESULTS
Eleven of 6821 vaccinated patients (0.16%) developed delayed skin reactions after either the first or second dose of the mRNA-1273 vaccine against SARS-CoV-2. Eight of 11 patients (73%) developed a rash after the first dose, while in 3/11 (27%), the rash occurred after the second dose. More females (9/11) were affected. Four of 11 patients required antihistamines, with two needing additional topical steroids. All the cutaneous manifestations resolved within 14 days. None of the skin reactions after the first dose of the vaccine prevented the administration of the second dose. There were no long-term cutaneous sequelae in any of the affected individuals.
CONCLUSION
CONCLUSIONS
Our data suggests that skin reactions after the use of mRNA-1273 vaccine against SARS-CoV-2 are possible, but rare. Further studies need to be done to understand the pathophysiology of these lesions.
Identifiants
pubmed: 34433495
doi: 10.1186/s40001-021-00557-z
pii: 10.1186/s40001-021-00557-z
pmc: PMC8386154
doi:
Substances chimiques
COVID-19 Vaccines
0
Histamine Antagonists
0
Steroids
0
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
98Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
Am J Surg Pathol. 2021 Mar 1;45(3):293-303
pubmed: 33399338
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
J Am Acad Dermatol. 2002 Dec;47(6):898-907
pubmed: 12451376
Dermatol Ther (Heidelb). 2021 Jun;11(3):695-705
pubmed: 33811315
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2480-2481
pubmed: 33864927
J Allergy Clin Immunol. 2005 Jun;115(6):1268-75
pubmed: 15940146
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Am J Pathol. 2021 Aug;191(8):1374-1384
pubmed: 34033751
Vaccine. 2007 Aug 1;25(31):5675-84
pubmed: 17448577
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1423-1437
pubmed: 33388478
Am J Dermatopathol. 2020 Aug;42(8):564-570
pubmed: 32701690
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1438-1441
pubmed: 33529722
N Engl J Med. 2021 Apr 1;384(13):1273-1277
pubmed: 33657292
J Eur Acad Dermatol Venereol. 2021 Mar;35(3):e187-e189
pubmed: 33002210
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e425-e427
pubmed: 33783873
JAAD Case Rep. 2021 Apr;10:92-95
pubmed: 33748377